Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More

Welcome to Benzinga’s psychedelic headlines roundup. This is our pick of must-read news items concerning the last two weeks of February 2024.

See previous edition Psychedelics Headlines: Trauma-Informed Care, Valentine’s Day & MDMA, Academics On Drugs

Research

Validation of the Psychedelic Predictor Scale (original read.)
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin [Research funded by Brain and Cognition Discovery Foundation (BCDF), Usona, and Braxia Scientific (OTC:BRAXF).]
Development of a digital intervention for psychedelic preparation (DIPP) (read.)
Critical Psychedelic Studies: Correcting the Hype, a symposium organized by Harvard’s Petrie Flom Center (access essays.)
Psilocybin and the Development of Serotonin Toxicity (case report.)

Tune In, Get Smart

This Test Predicts How Ready You Are for a Psychedelic Experience, by Psychedelic Vantage (read.)
Beyond the Psychedelic Competitive Moat: Chasing the Patent Dragon, on Harvard’s Petrie Flom Center (read.)
There’s no such thing as ‘evidence-based’ drug policy, by Criminal Justice Prof. Alex Stevens for Transforming Society (read.)
The Most Common Extended Difficulties Following Psychedelic Use, by Sam …

Full story available on Benzinga.com